Double-blind placebo-controlled trial of pentoxifylline added to risperidone: Effects on aberrant behavior in children with autism

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 1, 2010, Pages 32-36

  Akhondzadeh, Shahin ^a   Fallah, Jalil ^a   Mohammadi, Mohammad Reza ^a   Imani, Reza ^a   Mohammadi, Mohammad ^a   Salehi, Bahman ^b   Ghanizadeh, Ahmad ^c   Raznahan, Maedeh ^a   Mohebbi Rasa, Soodeh ^a   Rezazadeh, Shams Ali ^d   Forghani, Saeedeh ^e  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ARAK UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Institute of Medicinal Plants Iran   (Iran)

^e RAZI VACCINE AND SERUM RESEARCH INSTITUTE   (Iran)

Author keywords

Autism; Clinical trial; Immune system; Pentoxifylline

Indexed keywords

PENTOXIFYLLINE; PLACEBO; RISPERIDONE;

ANOREXIA; ARTICLE; AUTISM; CHILD; CHILD BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE TITRATION; DRUG RESPONSE; FATIGUE; FEMALE; HUMAN; HYPERACTIVITY; INCREASED APPETITE; IRRITABILITY; LETHARGY; MALE; OUTCOME ASSESSMENT; PSYCHOSOCIAL WITHDRAWAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SIDE EFFECT; SPEECH DISORDER; STEREOTYPY; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; BEHAVIORAL SYMPTOMS; CHILD; CHILD, PRESCHOOL; DEVELOPMENTAL DISABILITIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; RETROSPECTIVE STUDIES; RISPERIDONE; TREATMENT OUTCOME;

EID: 73849147822     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.09.012     Document Type: Article

References (26)

1. Akhondzadeh S., Erfani S., Mohammadi M.R., Tehranidoost M., and Amini H. Cyproheptadine in the treatment of autistic disorder: a double-blind and placebo controlled trial. J Clin Pharm Ther 29 (2004) 145-150
2. Akhondzadeh S., Tabatabaee M., Amini H., Ahmadi Abhari S.A., Abbasi S.H., and Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 90 (2007) 179-185
3. Akhondzadeh S., Tajdar H., Mohammadi M.R., Mohammadi M., Nouroozinejad G.H., Shabstari O.L., et al. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry Hum Dev 39 (2008) 237-245
4. Akhondzadeh S., Jafari S., Raisi F., Nasehi A.A., Ghoreishi A., Salehi B., et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 26 (2009) 607-611
5. Aman M.G., Singh N.N., Stewart A.W., and Field C.J. The aberrant behavior checklist: a behavior rating scale for assessment of treatment effects. Am J Ment Defic 89 (1985) 485-491
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (2000), AmericanPsychiatric Press, Washington
7. Barnard L., Young A.H., Pearson J., Geddes J., and O'Brien G. A systematic review of the use of atypical antipsychotics in autism. J Psychopharmacol 16 (2002) 93-101
8. Canitano R., and Scandurra V. Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents. Neuropsychiatr Dis Treat 4 (2008) 723-730
9. Chouinard G., Ross-Chouinard A., Annables L., and Jones B.D. Extrapyramidal symptoms rating scale (abstract). Can J Neurol Sci 7 (1980) 233
10. Gupta S. Immunological treatments for autism. J Autism Dev Disord 30 (2000) 475-479
11. Gupta S., Rimland B., and Shilling P.D. Pentoxyfylline: a brief review and rationale for its possible use in the treatment of autism. J Child Neurol 11 (1996) 501-504
12. Hawkins E.S., and Ribeiro H.A. Pentoxifylline review. J Am Podiatr Med Assoc 77 (1987) 645-647
13. Leskovec T.J., Rowles B.M., and Findling R.L. Pharmacological treatment options for autism spectrum disorders in children and adolescents. Harv Rev Psychiatry 16 (2008) 97-112
14. Levy S.E., and Hyman S.L. Novel treatments for autistic spectrum disorders. Men Retard Dev disabil 11 (2005) 131-142
15. Mohammadi M.R., and Akhondzadeh S. Autism spectrum disorders: etiology and pharmacotherapy. Curr Drug Ther 2 (2007) 97-103
16. Myers S.M. The status of pharmacotherapy for autism spectrum disorders. Expert Opin Pharmacother 8 (2007) 1579-1603
17. Nakane A. Effect of pentoxifylline in autistic children. Tokyoto Eisei Gakkashi 65 (1980) 104-105
18. Polleux F., and Lauder J.M. Toward a developmental neurobiology of autism. Men Retard Dev Disabil 10 (2005) 303-317
19. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blindeddiscontinuation after 6 months. Am J Psychiatry 162 (2005) 1361-1369
20. Seasick M., Nakazima K., and Sugiyama A. On the effects of pentoxifylline upon the EEG activity of early infantile autism, abstract. Brain Dev 6 (1984) 156
21. Shea S., Turgay A., Carroll A., Schulz M., Orlik H., Smith I., et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114 (2004) e634-e641
22. Shimoide M. Effect of pentoxifylline (Trental) on infantile autism. Clin Exp Med 58 (1981) 285-288
23. Sogame S. Clinical experiences with administration of pentoxifylline against autism and behaviour abnormalities. Jpn J Child Psych 19 (1978) 137-144
24. Sperner-Unterweger B. Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications. Drugs 65 (2005) 1493-1520
25. Sperner-Unterweger B., Winkler C., and Fuchs D. Immune activation in autism. Pediatr Neurol 34 (2006) 333
26. Turek S. Treatment of psychotic and autistic children with pentoxifylline. ASANA 1 (1981) 51-60